[Skip to Content]
[Skip to Content Landing]
Comment & Response
March 2016

Effects of Standard Treatments for Ductal Carcinoma In Situ—Making Informed Choices

Author Affiliations
  • 1Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Falmer, United Kingdom
  • 2Department of Surgery, Queen Elizabeth Hospital, Edgebaston, Birmingham, United Kingdom
  • 3Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
JAMA Oncol. 2016;2(3):396-397. doi:10.1001/jamaoncol.2015.4857

To the Editor Discussions around the diagnosis, treatment, and outcomes after a diagnosis of ductal carcinoma in situ (DCIS) continue to generate great interest. Narod and colleagues1 confirm findings from other studies that have repeatedly shown a low breast cancer–specific mortality following a diagnosis of DCIS (3.3% at 20 years) and support the need to reconsider the management of DCIS.